NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty and
other violations of law by the Board of Achillion Pharmaceuticals,
Inc. ("ACHN" or the "Company") (NASDAQ: ACHN) in connection with
the proposed acquisition of the Company by Alexion Pharmaceuticals,
Inc. ("ALXN") (NASDAQ: ALXN). Under the terms of the
acquisition agreement, ACHN shareholders will receive $6.30 cash for each ACHN share they
own.
If you own ACHN shares and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, visit our website:
http://www.weisslawllp.com/achillion-pharmaceuticals-inc/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888)
593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether ACHN's Board acted to maximize
shareholder value prior to entering into the acquisition
agreement. Notably, the Company currently has two clinical
stage treatments in development, including Danicopan, a lead drug
candidate which has been designated as a Breakthrough Therapy by
the U.S. Food and Drug Administration ("FDA") for treatment of
patients with a rare blood disorder called paroxysmal nocturnal
hemoglobinuria, or PNH. Receiving Breakthrough Therapy
designation from the FDA indicates preliminary clinical evidence
has demonstrated the drug may provide substantial improvement on at
least one clinically significant endpoint compared with currently
available therapy.
Given these facts, WeissLaw is concerned whether the proposed
acquisition undervalues the Company, and whether all material
information related to the proposed acquisition is fully and fairly
disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-achillion-pharmaceuticals-inc-300941386.html
SOURCE WeissLaw LLP
